10-K: Passage Bio Reports 2024 Results, Outlines Strategy for PBFT02 Development

Passage Bio focuses on PBFT02 development for neurodegenerative diseases after out-licensing pediatric programs.

Summary

• Passage Bio, a clinical-stage genetic medicines company, released its 10-K filing for the fiscal year ended December 31, 2024.
• The company is prioritizing the development of PBFT02, a gene replacement therapy, for frontotemporal dementia (FTD) and exploring its potential in other neurodegenerative indications like FTD-C9orf72, ALS, and Alzheimer's disease (AD).
• In January 2025, Passage Bio reported positive biomarker data from the upliFT-D trial, showing robust and durable increases in CSF PGRN levels in FTD-GRN patients treated with Dose 1 of PBFT02.
• The company out-licensed its clinical-stage pediatric programs in GM1, Krabbe disease, and MLD to Gemma Biotherapeutics in July 2024, receiving initial payments of $10.0 million.
• A restructuring plan approved in January 2025 included a 55% workforce reduction to reduce operating expenses.
• As of December 31, 2024, Passage Bio's cash, cash equivalents, and marketable securities totaled $76.8 million, expected to fund operations into the first quarter of 2027.
• The company incurred a net loss of $64.8 million for the year ended December 31, 2024, compared to a net loss of $102.1 million for the year ended December 31, 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. Positive clinical data and out-licensing deals are offset by financial losses, restructuring, and risks associated with drug development and regulatory approval.

Positives

• Robust and durable increases in CSF PGRN levels observed in FTD-GRN patients treated with PBFT02.
• Reduction in plasma NfL levels suggests potential for slowing disease progression.
• Out-licensing of pediatric programs provides upfront capital and potential future milestone and royalty payments.
• Positive regulatory feedback received on the clinical pathway to treating FTD-C9orf72 and ALS with PBFT02.
• Existing cash runway extends into the first quarter of 2027.

Negatives

• Two patients experienced serious adverse events (venous sinus thrombosis and hepatotoxicity) during the upliFT-D trial, leading to a revised immunosuppression regimen.
• The company has a history of operating losses and may not achieve or sustain profitability.
• PBFT02 is the sole clinical-stage product candidate, increasing the risk profile.
• The price of the company's common stock does not meet the requirements for continued listing on The Nasdaq Capital Market.

Risks

• Clinical trials may be delayed or unsuccessful, and regulatory approvals may not be obtained.
• Gene therapy is a novel technology, making it difficult to predict the time and cost of product candidate development.
• Product candidates may cause undesirable side effects, limiting commercial potential.
• Manufacturing problems could result in delays or harm the business.
• The company faces significant competition in a rapidly changing technological environment.
• The company relies on third-party manufacturers, which could lead to supply chain issues.
• Unfavorable pricing regulations or third-party coverage and reimbursement policies could harm the business.
• Failure to obtain and maintain patent protection could allow competitors to commercialize similar products.
• The company may need to raise additional funding, which may not be available on acceptable terms.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditure requirements into the first quarter of 2027. They plan to report 12-month safety and biomarker data from Dose 1 patients and interim safety and biomarker data from Dose 2 patients in the second half of 2025 and seek regulatory feedback on registrational trial design in the first half of 2026.

Management Comments

• Patients are considered in every decision we make.
• We believe that genetic medicines have the potential to significantly change the course of neurodegenerative diseases and to transform patients lives.
• We are prioritizing the execution of the ongoing upliFT-D study, with the goal of advancing this program to the registrational phase.
• We believe that our approach of advancing one genetic medicine candidate to treat multiple indications is a cost-effective strategy.

Industry Context

The biotechnology and pharmaceutical industries, including the genetic medicines field, are characterized by rapidly changing technologies, competition, and a strong emphasis on intellectual property. The company faces competition from other companies developing gene therapies and methods for modifying genes and regulating gene expression.

Comparison to Industry Standards

• Competitors in the FTD-GRN space include Prevail Therapeutics (part of Eli Lilly & Co), AviadoBio Ltd, Alector, Inc. (partnered with GSK plc), Kyowa Kirin Co., Ltd., QurAlis Corporation, Denali Therapeutics Inc. (partnered with Takeda Pharmaceutical Company Limited), and Vesper Bio ApS.
• Competitors in the FTD-C9orf72 space include Transposon Therapeutics, Inc. and Alector, Inc. (partnered with GSK plc).

Legal Proceedings

• The company is a defendant in litigation with a former employee, who filed a lawsuit in the Court of Common Pleas of Philadelphia County asserting claims for breach of contract and violation of the Pennsylvania Wage Payment and Collection Law. The plaintiff filed an appeal with the Superior Court of Pennsylvania, which is currently pending.

Stakeholder Impact

• The company's mission is to improve the lives of patients with neurodegenerative diseases.
• The restructuring plan included a reduction of 55% in the company's workforce.

Next Steps

• Report 12-month safety and biomarker data from Dose 1 patients and interim safety and biomarker data from Dose 2 patients in the second half of 2025.
• Seek regulatory feedback on registrational trial design in the first half of 2026.
• Initiate dosing of FTD-C9orf72 patients in the first half of 2025.

Key Dates